Illustration — photo to followLot AV-CGS-2609-A
CagriSema
Cagrilintide + semaglutide · 20 mg / 3 mL
VAT included · 1 pen · 20 mg / 3 mL
Sold for research use only. Not a medicine and not authorised for human consumption. Purchasers must be 18+ and confirm intended use at checkout.
Investigational combination — not authorised anywhere. Semaglutide on its own is authorised as a medicine elsewhere; this pen is a research product, not the licensed medicine.
- Ships chilled · same-day dispatch before 2 pm
- Free UK shipping over £300
About
What this is
CagriSema is included in the guide under metabolic & weight. The reference focuses on amylin and glp-1 signalling in metabolic research and distinguishes biological rationale from demonstrated outcomes. Supplied by the manufacturer as a pre-filled 20 mg / 3 mL dose-dial pen for research use — no reconstitution, no vials, no drawing up. Our evidence records for each component are linked below and graded on the same scale as every compound on this site.
- 01Pre-filled pen — no reconstitution
- 02Identity confirmed by LC-MS per lot
- 03Purity ≥ 99% by HPLC per component
- 04Certificate published against the lot number
Specification
What's in the pen
| Component | Amount | What it is | Evidence · Weight | |
|---|---|---|---|---|
| Cagrilintide | See lot certificate | Long-acting amylin analogue | Moderate | Record |
| Semaglutide | See lot certificate | GLP-1 receptor agonist | Strong | Record |
Amounts are per pen. Where the composition states no split, the component amounts are on the lot certificate.
Device
How the pen works
- 01
Attach a pen needle
Take the cap off, wipe the septum with an alcohol swab and screw a compatible pen needle on until it seats. Use a fresh needle every time and never share a pen.
- 02
Prime
Dial a small test amount, hold the pen needle-up and press the button until a drop appears at the tip. This clears air from the needle and confirms the pen delivers.
- 03
Dial
Turn the dial to the volume you intend to deliver; the window shows the setting in the pen's increments. The dial sets a volume of solution — nothing more.
- 04
Inject
Insert as the pen-needle instructions describe, press the button fully and hold for ten seconds before withdrawing. Remove and bin the needle in a sharps container, recap and refrigerate.
Dosing is not provided; see the research information in the evidence record. These steps describe how the device operates, not how or whether to use its contents.
Certificate of analysis · 2 components tested
Lot AV-CGS-2609-A
Independent test of a sample from lot AV-CGS-2609-A of CagriSema. Each component is identified by LC-MS and its purity reported separately; endotoxin is measured on the finished solution. Testing says what is in the pen, not whether the combination is safe or does anything in people. How we test
Evidence record · reviewed 1 Sept 2026 · 2 components
What the research says about each component
Each component has its own record. The combination in this pen has not been studied in people, so the grades below are per component, not for the blend.
Cagrilintide
Long-acting amylin analogue
Investigational weekly amylin analogue, studied alone and with semaglutide (CagriSema).
- Overall evidence
- Moderate
- Human evidence
- Late-stage clinical trials
- Regulatory · jurisdictions on record
- Investigational
- Investigational · United Kingdom, United States, European Union, Australia and Canada
- United Kingdom · Not authorised; in phase 3 trials (REDEFINE programme). · reviewed 1 Sept 2026
- Anti-doping · WADA
- Not on the Prohibited List
Cagrilintide + Semaglutide · Studied together in people
The fixed combination CagriSema (2.4 mg + 2.4 mg) has phase 3 data (REDEFINE 1 and 2) and is under FDA review, but it remains investigational and is not authorised anywhere.
Semaglutide
GLP-1 receptor agonist
Once-weekly incretin medicine with the largest weight-management evidence base.
- Overall evidence
- Strong
- Human evidence
- Approved medicine (for specific indications)
- Regulatory · jurisdictions on record
- Authorised
- Authorised · United Kingdom, United States, European Union, Australia and Canada
- United Kingdom · Authorised (MHRA) for type 2 diabetes and weight management; prescription-only. · reviewed 1 Sept 2026
- Anti-doping · WADA
- Not on the Prohibited List
Fit
Who this is for
Weight and appetite goals where the amylin + GLP-1 combination is the interest — phase 3 data for the combination exists, but it is not authorised.
- Weight management where appetite is the main driver
- Interest in the studied amylin + GLP-1 combination
- Metabolic health alongside weight
Check your fit
The Peptide Checkup maps your goal and history against the evidence for this pen and tells you if it is a poor fit — even after you have bought it.
Check your fit · 7 minutesAlso in the range · by shared goal, then bestsellers
5 related pens
- Illustration — photo to follow
Semaglutide
Peptide pen · 10 mg / 3 mL
£265 
Retatrutide (R3T)
Peptide pen · 40 mg / 3 mL
£370- Illustration — photo to follow
Liraglutide
Peptide pen · 18 mg / 3 mL
£235 - Illustration — photo to follow
Tirzepatide
Peptide pen · 30 mg / 3 mL
£320 
Tesamorelin
Peptide pen · 20 mg / 3 mL
£255